Systematic review: Instruments to assess abdominal pain in irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 9, 2015, Pages 1064-1081

  Mujagic, Z ^a   Keszthelyi, D ^a   Aziz, Q ^b   Reinisch, W ^c,d   Quetglas, E G ^e   De Leonardis, F ^e   Segerdahl, M ^e,f   Masclee, A A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MCMASTER UNIVERSITY   (Canada)

^e GRÜNENTHAL GMBH   (Germany)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ARTICLE; ASSESSMENT OF HUMANS; BOWEL DISEASE QUESTIONNAIRE; BOWEL SYMPTOM QUESTIONNAIRE; BRIEF PAIN INVENTORY; CHRONIC PAIN; CLINICAL ASSESSMENT TOOL; DATA ANALYSIS; FUNCTIONAL BOWEL DISORDER SEVERITY INDEX; GASTROINTESTINAL SYMPTOM RATING SCALE; GASTROINTESTINAL SYMPTOM RATING SCALE IRRITABLE BOWEL SYNDROME; GASTROINTESTINAL SYMPTOM SEVERITY QUESTIONNAIRE; HUMAN; IRRITABLE BOWEL SYNDROME SYMPTOM SEVERITY SCALE; IRRITABLE COLON; MCGILL PAIN QUESTIONNAIRE; MEASUREMENT; NUMERIC RATING SCALE; PAIN ASSESSMENT; PAIN DISCOMFORT SCALE; PAIN SEVERITY SCALE OF THE WEST HAVEN YALE MULTIDIMENSIONAL PAIN INVENTORY; PAIN SEVERITY SCALE OF THE WHYMPI; PAIN THRESHOLD; PAIN VIGILANCE AND AWARENESS QUESTIONNAIRE; PRIORITY JOURNAL; PROVOCATION TEST; RETROSPECTIVE STUDY; SYMPTOM SEVERITY MEASURES FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION; SYSTEMATIC REVIEW; VALIDATION PROCESS; VERBAL RATING SCALE; VISUAL ANALOG SCALE; VISUAL ANALOGUE SCALE FOR IRRITABLE BOWEL SYNDROME; ADULT; AGED; FACTUAL DATABASE; MIDDLE AGED; PAIN MEASUREMENT; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; VERY ELDERLY; VISCERAL PAIN;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PAIN MEASUREMENT; SURVEYS AND QUESTIONNAIRES; VISCERAL PAIN;

EID: 84942894205     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13378     Document Type: Article

References (155)

1. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L,. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-43.
2. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms / prepared by the International Association for the Study of Pain, Task Force on Taxonomy; editors, Harold Merskey, N. Bogduk.-2nd ed. 1994 ISBN 0-931092-05-1.
3. Treede RD, Rief W, Barke A, et al., A classification of chronic pain for ICD-11. Pain 2015; 156: 1003-7.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
5. Fornasari D,. Pain mechanisms in patients with chronic pain. Clin Drug Investig 2012; 32 (Suppl. 1): 45-52.
6. Cervero F,. Visceral versus somatic pain: similarities and differences. Dig Dis 2009; 27 (Suppl. 1): 3-10.
7. Loeser JD, Treede RD,. The Kyoto protocol of IASP basic pain terminology. Pain 2008; 137: 473-7.
8. Keszthelyi D, Troost FJ, Simren M, et al., Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain 2012; 16: 1444-54.
9. Melzack R,. Sensory, Motivational and Central Control Determinants of Pain: A New Conceptual Model. The Skin Senses. Springfield, IL: Charles C Thomas, 1968; 423-43.
10. Simren M, Mansson A, Langkilde AM, et al., Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63: 108-15.
11. Dworkin RH, Turk DC, Peirce-Sandner S, et al., Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012; 153: 1148-58.
12. Lawshe CH,. A quantitative approach to content validity. Personnel Psychol 1975; 28: 563-75.
13. Campell DT, Fiske DW,. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 1959; 56: 81-105.
14. Pearson K,. On Further Methods of Determining. Correlation Draper's Company Research Memoirs (Biometric Series IV). London: Dulau and Co Cambridge, 1907; 39.
15. Cronbach LJ, Warrington WG,. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika 1951; 16: 167-88.
16. Atkinson G, Nevill AM,. Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine. Sports Med 1998; 26: 217-38.
17. Hjermstad MJ, Fayers PM, Haugen DF, et al., Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 2011; 41: 1073-93.
18. Guthrie E, Barlow J, Fernandes L, et al., Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome. Psychosom Med 2004; 66: 578-82.
19. Tanum L, Malt UF,. Personality and physical symptoms in nonpsychiatric patients with functional gastrointestinal disorder. J Psychosom Res 2001; 50: 139-46.
20. Saggioro A,. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38 (6 Suppl.): S104-6.
21. Chassany O, Bonaz B, Bruley DESVS, et al., Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2007; 25: 1115-23.
22. Simren M, Agerforz P, Bjornsson ES, Abrahamsson H,. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil 2007; 19: 20-9.
23. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al., Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
24. Muller-Lissner S, Koch G, Talley NJ, et al., Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003; 56: 310-6.
25. Klooker TK, Kuiken SD, Lei A, Boeckxstaens GE,. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 605-15.
26. Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H,. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009; 29: 198-206.
27. Gonlachanvit S, Mahayosnond A, Kullavanijaya P,. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil 2009; 21: 23-32.
28. Khalif IL, Guigley EMM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA,. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). J Gastrointestin Liver Dis 2009; 18: 17-22.
29. Kim ES, Cheon JH, Park JJ, et al., Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception. J Gastroenterol Hepatol 2010; 25: 1232-8.
30. Imai A, Kato M, Ono S, Shimizu Y, Takeda H, Asaka M,. Efficacy of carbon dioxide-insufflating colonoscopy in patients with irritable bowel syndrome: a randomized double-blind study. J Gastroenterol Hepatol 2012; 27: 1623-8.
31. Farnam A, Somi MH, Farhang S, Mahdavi N, Ali Besharat M,. The therapeutic effect of adding emotional awareness training to standard medical treatment for irritable bowel syndrome: a randomized clinical trial. J Psychiatr Pract 2014; 20: 3-11.
32. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG,. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75 e5.
33. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD,. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med 2007; 69: 89-98.
34. Lackner JM, Jaccard J, Blanchard EB,. Testing the sequential model of pain processing in irritable bowel syndrome: a structural equation modeling analysis. Eur J Pain 2005; 9: 207-18.
35. Spiegel B, Bolus R, Harris LA, et al., Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009; 30: 1159-70.
36. Spiegel BMR, Bolus R, Harris LA, et al., Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment Pharmacol Ther 2010; 32: 1192-202.
37. Masand PS, Pae CU, Krulewicz S, et al., A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 2009; 50: 78-86.
38. Craske MG, Wolitzky-Taylor KB, Labus J, et al., A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther 2011; 49: 413-21.
39. Hellstrom PM, Saito YA, Bytzer P, Tack J, Mueller-Lissner S, Chang L,. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. Am J Gastroenterol 2011; 106: 1299-307.
40. Rao S, Lembo AJ, Shiff SJ, et al., A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-24; quiz p. 25.
41. Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC,. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome-a pilot study. Scand J Gastroenterol 2012; 47: 1159-64.
42. Bouchoucha M, Fysekidis M, Devroede G, Raynaud JJ, Bejou B, Benamouzig R,. Abdominal pain localization is associated with non-diarrheic Rome III functional gastrointestinal disorders. Neurogastroenterol Motil 2013; 25: 686-93.
43. Lacy BE, Wang F, Bhowal S, Schaefer E, Study Group. On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. Scand J Gastroenterol 2013; 48: 926-35.
44. Lackner JM, Quigley BM,. Pain catastrophizing mediates the relationship between worry and pain suffering in patients with irritable bowel syndrome. Behav Res Ther 2005; 43: 943-57.
45. Lackner JM, Jaccard J, Keefer L, et al., The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports. Neurogastroenterol Motil 2014; 26: 1802-11.
46. Chey WD, Lembo AJ, Lavins BJ, et al., Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
47. Brown PM, Drossman DA, Wood AJ, et al., The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011; 141: 507-16.
48. Akbar A, Yiangou Y, Facer P, et al., Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010; 59: 767-74.
49. Melzack R,. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-7.
50. Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG Jr, Hudson JI,. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009; 24: 423-8.
51. Cleeland CS, Ryan KM,. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38.
52. Seres G, Kovacs Z, Kovacs A, et al., Different associations of health related quality of life with pain, psychological distress and coping strategies in patients with irritable bowel syndrome and inflammatory bowel disorder. J Clin Psychol Med Settings 2008; 15: 287-95.
53. Kerns RD, Turk DC, Rudy TE,. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 1985; 23: 345-56.
54. Jensen MP, Karoly P, Harris P,. Assessing the affective component of chronic pain: development of the Pain Discomfort Scale. J Psychosom Res 1991; 35: 149-54.
55. McCracken LM,. 'Attention' to pain in persons with chronic pain: a behavioural approach. Behav Ther 1997; 28: 271-84.
56. Labus JS, Bolus R, Chang L, et al., The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004; 20: 89-97.
57. Jerndal P, Ringstrom G, Agerforz P, et al., Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil 2010; 22: 646-e179.
58. Bengtsson M, Ohlsson B, Ulander K,. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol 2007; 7: 16.
59. Bengtsson M, Hammar O, Mandl T, Ohlsson B,. Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS). BMC Gastroenterol 2011; 11: 122.
60. Svedlund J, Sjodin I, Dotevall G,. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34.
61. Kuiken SD, Tytgat GN, Boeckxstaens GE,. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-28.
62. Kuiken SD, Lindeboom R, Tytgat GN, Boeckxstaens GE,. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 157-64.
63. Ludidi S, Mujagic Z, Jonkers D, et al., Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 1104-11.
64. Mujagic Z, Ludidi S, Keszthelyi D, et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther 2014; 40: 288-97.
65. Ludidi S, Jonkers DM, Koning CJ, et al., Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014; 26: 705-14.
66. Mujagic Z, Leue C, Vork L, et al., The Experience Sampling Method-a new digital tool for momentary symptom assessment in IBS: an exploratory study. Neurogastroenterol Motil 2015; doi: 10.1111/nmo.12624. [Epub ahead of print]
67. Revicki DA, Wood M, Wiklund I, Crawley J,. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Quality Life Res 1998; 7: 75-83.
68. Wiklund IK, Fullerton S, Hawkey CJ, et al., An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol 2003; 38: 947-54.
69. Posserud I, Syrous A, Lindstrom L, Tack J, Abrahamsson H, Simren M,. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-23.
70. Francis CY, Morris J, Whorwell PJ,. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
71. Sabate JM, Veyrac M, Mion F, et al., Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 484-90.
72. Kanazawa M, Palsson OS, Thiwan SI, et al., Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 2550-61.
73. Sondergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R,. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011; 46: 663-72.
74. Annahazi A, Ferrier L, Bezirard V, et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol 2013; 108: 1322-31.
75. Williams VS, Nelson LM, Fehnel SE, et al., Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2014; 40: 298-308.
76. Drossman DA, Li ZM, Toner BB, et al., Functional bowel disorders-a multicenter comparison of health-status and development of illness severity index. Dig Dis Sci 1995; 40: 986-95.
77. Talley NJ, Phillips SF, Melton LJ, Wiltgen C, Zinsmeister AR,. A patient questionnaire to identify bowel-disease. Ann Intern Med 1989; 111: 671-4.
78. Neri M, Laterza F, Howell S, et al., Symptoms discriminate irritable bowel syndrome from organic gastrointestinal diseases and food allergy. Eur J Gastroenterol Hepatol 2000; 12: 981-8.
79. Barbara G, Stanghellini V, De Giorgio R, et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
80. Talley NJ, Phillips SF, Bruce B, Twomey CK, Zinsmeister AR, Melton LJ 3rd,. Relation among personality and symptoms in nonulcer dyspepsia and the irritable bowel syndrome. Gastroenterology 1990; 99: 327-33.
81. Talley NJ, Boyce PM, Owen BK, Newman P, Paterson KJ,. Initial validation of a bowel symptom questionnaire and measurement of chronic gastrointestinal symptoms in Australians. Aust N Z J Med 1995; 25: 302-8.
82. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA,. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94: 2929-35.
83. Tan S, Tillisch K, Bolus SR, et al., Traditional Chinese medicine based subgrouping of irritable bowel syndrome patients. Am J Chin Med 2005; 33: 365-79.
84. Roalfe AK, Roberts LM, Wilson S,. Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol 2008; 8: 30.
85. Zhu Y, Wu Z, Ma X, et al., Brain regions involved in moxibustion-induced analgesia in irritable bowel syndrome with diarrhea: a functional magnetic resonance imaging study. BMC Complement Altern Med 2014; 14: 500.
86. Ljotsson B, Hesser H, Andersson E, et al., Provoking symptoms to relieve symptoms: a randomized controlled dismantling study of exposure therapy in irritable bowel syndrome. Behav Res Ther 2014; 55: 27-39.
87. Fassov J, Lundby L, Worsoe J, Buntzen S, Laurberg S, Krogh K,. A randomised, controlled study of small intestinal motility in patients treated with sacral nerve stimulation for irritable bowel syndrome. BMC Gastroenterol 2014; 14: 111.
88. Weinland SR, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Drossman DA,. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. Am J Gastroenterol 2011; 106: 1813-20.
89. van der Veek PP, Van Rood YR, Masclee AA,. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 321-8.
90. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J,. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with IBS. Gastroenterology 1999; 116: 38-45.
91. Lembo T, Naliboff BD, Matin K, et al., Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000; 87: 137-47.
92. Ritchie J,. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-32.
93. Whitehead WE, Holtkotter B, Enck P, et al., Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-92.
94. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA,. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
95. Munakata J, Naliboff B, Harraf F, et al., Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 55-63.
96. Naliboff BD, Munakata J, Fullerton S, et al., Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997; 41: 505-12.
97. Hammer HF, Phillips SF, Camilleri M, Hanson RB,. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol 1998; 274: G584-90.
98. Chang L, Munakata J, Mayer EA, et al., Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000; 47: 497-505.
99. Chang FY, Lu CL, Chen CY, Luo JC,. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007; 22: 2266-72.
100. Simren M, Abrahamsson H, Bjornsson ES,. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20-7.
101. Verne GN, Robinson ME, Price DD,. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93: 7-14.
102. Verne GN, Price DD, Callam CS, Zhang B, Peck J, Zhou Q,. Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors. J Pain 2012; 13: 901-9.
103. Bernstein CN, Frankenstein UN, Rawsthorne P, Pitz M, Summers R, McIntyre MC,. Cortical mapping of visceral pain in patients with GI disorders using functional magnetic resonance imaging. Am J Gastroenterol 2002; 97: 319-27.
104. Bouin M, Plourde V, Boivin M, et al., Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-7.
105. Spetalen S, Jacobsen MB, Vatn MH, Blomhoff S, Sandvik L,. Visceral sensitivity in irritable bowel syndrome and healthy volunteers: reproducibility of the rectal barostat. Dig Dis Sci 2004; 49: 1259-64.
106. Posserud I, Agerforz P, Ekman R, Bjornsson ES, Abrahamsson H, Simren M,. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102-8.
107. Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J,. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 237-46.
108. Coffin B, Bouhassira D, Sabate JM, Barbe L, Jian R,. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004; 53: 1465-70.
109. Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A,. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53: 1595-601.
110. Caldarella MP, Milano A, Laterza F, et al., Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion. Am J Gastroenterol 2005; 100: 383-9.
111. Caldarella MP, Giamberardino MA, Sacco F, et al., Sensitivity disturbances in patients with irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2006; 101: 2782-9.
112. Cremonini F, Houghton LA, Camilleri M, et al., Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 2005; 17: 810-20.
113. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H,. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-7.
114. Lee KJ, Kim JH, Cho SW,. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 981-8.
115. Vase L, Robinson ME, Verne GN, Price DD,. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005; 115: 338-47.
116. Frokjaer JB, Andersen SD, Gale J, Arendt-Nielsen L, Gregersen H, Drewes AM,. An experimental study of viscero-visceral hyperalgesia using an ultrasound-based multimodal sensory testing approach. Pain 2005; 119: 191-200.
117. Ng C, Malcolm A, Hansen R, Kellow JE,. Distension technique influences the relationship between colonic and rectal hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 206-10.
118. Song GH, Venkatraman V, Ho KY, Chee MW, Yeoh KG, Wilder-Smith CH,. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain 2006; 126: 79-90.
119. Moshiree B, Price DD, Robinson ME, Gaible R, Verne GN,. Thermal and visceral hypersensitivity in irritable bowel syndrome patients with and without fibromyalgia. Clin J Pain 2007; 23: 323-30.
120. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD,. Effect of a second-generation alpha 2 delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56: 1218-25.
121. Dorn SD, Palsson OS, Thiwan SI, et al., Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-9.
122. van der Veek PP, Steenvoorden M, Steens J, van der Schaar PJ, Brussee J, Masclee AA,. Recto-colonic reflex is impaired in patients with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 653-9.
123. Ringel Y, Drossman DA, Leserman JL, et al., Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 2008; 134: 396-404.
124. Agrawal A, Houghton LA, Lea R, Morris J, Reilly B, Whorwell PJ,. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology 2008; 134: 1882-9.
125. Piche M, Arsenault M, Poitras P, Rainville P, Bouin M,. Widespread hypersensitivity is related to altered pain inhibition processes in irritable bowel syndrome. Pain 2010; 148: 49-58.
126. Elsenbruch S, Rosenberger C, Enck P, Forsting M, Schedlowski M, Gizewski ER,. Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010; 59: 489-95.
127. Elsenbruch S, Rosenberger C, Bingel U, Forsting M, Schedlowski M, Gizewski ER,. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010; 139: 1310-9.
128. Nozu T, Okumura T,. Visceral sensation and irritable bowel syndrome; with special reference to comparison with functional abdominal pain syndrome. J Gastroenterol Hepatol 2011; 26 (Suppl. 3): 122-7.
129. Vanhoutvin SA, Troost FJ, Kilkens TO, et al., Alternative procedure to shorten rectal barostat procedure for the assessment of rectal compliance and visceral perception: a feasibility study. J Gastroenterol 2012; 47: 896-903.
130. Ludidi S, Conchillo JM, Keszthelyi D, et al., Does meal ingestion enhance sensitivity of visceroperception assessment in irritable bowel syndrome? Neurogastroenterol Motil 2012; 24: 47-53, e3
131. Ludidi S, Conchillo JM, Keszthelyi D, et al., Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012; 24: 729-33, e345-6.
132. de Goncalves Medeiros MT, de Oliveira RB, dos Santos AA, et al., The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 577-86.
133. Benson S, Kattoor J, Wegner A, et al., Acute experimental endotoxemia induces visceral hypersensitivity and altered pain evaluation in healthy humans. Pain 2012; 153: 794-9.
134. Benson S, Kotsis V, Rosenberger C, et al., Behavioural and neural correlates of visceral pain sensitivity in healthy men and women: does sex matter? Eur J Pain 2012; 16: 349-58.
135. Letzen JE, Craggs JG, Perlstein WM, Price DD, Robinson ME,. Functional connectivity of the default mode network and its association with pain networks in irritable bowel patients assessed via lidocaine treatment. J Pain 2013; 14: 1077-87.
136. Aniwan S, Gonlachanvit S,. Effects of chili treatment on gastrointestinal and rectal sensation in diarrhea-predominant irritable bowel syndrome: a randomized, double-blinded, crossover study. J Neurogastroenterol Motil 2014; 20: 400-6.
137. van Wanrooij SJ, Wouters MM, Van Oudenhove L, et al., Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity? Am J Gastroenterol 2014; 109: 99-109.
138. Melchior C, Gourcerol G, Chastan N, et al., Effect of transcranial magnetic stimulation on rectal sensitivity in irritable bowel syndrome: a randomized, placebo-controlled pilot study. Colorectal Dis 2014; 16: O104-11.
139. Naliboff BD, Berman S, Suyenobu B, et al., Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006; 131: 352-65.
140. Rossel P, Drewes AM, Petersen P, Nielsen J, Arendt-Nielsen L,. Pain produced by electric stimulation of the rectum in patients with irritable bowel syndrome: further evidence of visceral hyperalgesia. Scand J Gastroenterol 1999; 34: 1001-6.
141. Brock C, Nissen TD, Gravesen FH, et al., Multimodal sensory testing of the rectum and rectosigmoid: development and reproducibility of a new method. Neurogastroenterol Motil 2008; 20: 908-18.
142. Thoua NM, Murray CD, Winchester WJ, et al., Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 552-60.
143. Arebi N, Bullas DC, Dukes GE, et al., Distinct neurophysiological profiles in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1086-93.
144. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment, 2012. Available at: https://federalregister.gov/a/2012-13143.
145. Lacy BE, Lembo AJ, Macdougall JE, et al., Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil 2014; 26: 326-33.
146. Melzack R,. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-99.
147. Byrne M, Troy A, Bradley LA, et al., Cross-validation of the factor structure of the McGill Pain Questionnaire. Pain 1982; 13: 193-201.
148. Mayer EA,. Emerging disease model for functional gastrointestinal disorders. Am J Med 1999; 107: 12S-9S.
149. Bradburn NM, Rips LJ, Shevell SK,. Answering autobiographical questions: the impact of memory and inference on surveys. Science 1987; 236: 157-61.
150. Thijssen AY, Jonkers DM, Leue C, et al., Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol 2010; 44: e236-41.
151. Comer SD, Zacny JP, Dworkin RH, et al., Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain 2012; 153: 2315-24.
152. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR,. Patient compliance with paper and electronic diaries. Control Clin Trials 2003; 24: 182-99.
153. Myin-Germeys I, Oorschot M, Collip D, Lataster J, Delespaul P, van Os J,. Experience sampling research in psychopathology: opening the black box of daily life. Psychol Med 2009; 39: 1533-47.
154. Stone AA, Broderick JE, Schwartz JE, Shiffman S, Litcher-Kelly L, Calvanese P,. Intensive momentary reporting of pain with an electronic diary: reactivity, compliance, and patient satisfaction. Pain 2003; 104: 343-51.
155. Whitehead WE, Palsson OS,. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115: 1263-71.